certolizumab pegol

Ligand id: 6774

Name: certolizumab pegol

Classification
Compound class Antibody
Approved drug? Yes (source: FDA (2008))
International Nonproprietary Names
INN number INN
8448 certolizumab pegol
Synonyms
CDP870
Cimzia®
PHA 738144
Database Links
Specialist databases
IMGT/mAb-DB 242
Other databases
PubChem SID 178103380
Search PubMed clinical trials certolizumab pegol
Search PubMed titles certolizumab pegol
Search PubMed titles/abstracts certolizumab pegol
Wikipedia Certolizumab_pegol
Comments
This therapeutic is a TNFα neutralising agent. Structurally it is a Fab' fragment of a TNFα-binding monoclonal antibody, which has polyethylene glycol (PEG) conjugated to a free cysteine residue in its hinge region (Cys227 of the heavy chain). Removing the Fc portion minimizes complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), two reactions known to cause unwanted side-effects in mAb therapies. PEGylation is used to increase the drug's half life, as Fab' fragments are normally rapidly degraded in vivo.